European Pharmaceutical Review

JUNE 24, 2022

This suggests that any of the modelled changes to the regulation could lead to a decrease in the number of OMPs developed… Some of the assessed changes to the regulation could undermine the business model under which OMP?focused Maarten has significant competition law experience in a variety of sectors. About the author. References.

Pharmaceutical 105

Pharmaceutical Medicine Marketing Competition 105

European Pharmaceutical Review

SEPTEMBER 14, 2023

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

Manufacturing 98

Manufacturing Management Engineering Pharmaceutical 98

European Pharmaceutical Review

JULY 4, 2024

11 The THR pathway was created with the purpose of establishing a simplified registration procedure for all traditional herbal medicines that do not fulfil the requirements for the MA (strict) pathway under Directive 2001/83/EC. She also holds post-graduate diplomas from Oxford (IP Law) as well as King’s College (EU Competition Law).

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

European Pharmaceutical Review

DECEMBER 19, 2022

1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.

Medicine 52

Medicine Biopharma Safety Food 52

Pharmaceutical Technology

FEBRUARY 13, 2023

The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active.

Competition 59

Competition Safety Patients Pharmaceutical 59

CloserIQ

OCTOBER 10, 2018

They’ve worked with leading clients such as Twitter and Mercedes Benz. Cybereason’s workplace culture is known to be fast-paced and competitive, with plenty of opportunities for learning. CloudHealth Technologies offers a market-leading cloud management platform that helps businesses optimize different cloud environments.

Sales 76

Sales Management Marketing Education 76

European Pharmaceutical Review

DECEMBER 14, 2023

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4

Medicine 116

Medicine Safety Competition Medical 116